Vyome Holdings, Inc. (HIND) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Vyome Holdings, Inc. stock (HIND) is currently trading at $2.29. Vyome Holdings, Inc. PS ratio (Price-to-Sales) is 40.15. Analyst consensus price target for HIND is $15.00. WallStSmart rates HIND as Sell.
- HIND PE ratio analysis and historical PE chart
- HIND PS ratio (Price-to-Sales) history and trend
- HIND intrinsic value — DCF, Graham Number, EPV models
- HIND stock price prediction 2025 2026 2027 2028 2029 2030
- HIND fair value vs current price
- HIND insider transactions and insider buying
- Is HIND undervalued or overvalued?
- Vyome Holdings, Inc. financial analysis — revenue, earnings, cash flow
- HIND Piotroski F-Score and Altman Z-Score
- HIND analyst price target and Smart Rating
Vyome Holdings, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Vyome Holdings, Inc. (HIND) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
Vyome Holdings, Inc. (HIND) Key Strengths (0)
Supporting Valuation Data
Vyome Holdings, Inc. (HIND) Areas to Watch (6)
Losing money on operations
Revenue declining -59.00%, a shrinking business
Very expensive at 40.1x annual revenue
Very expensive at 5.1x book value
Very low institutional interest at 1.92%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Vyome Holdings, Inc. (HIND) Detailed Analysis Report
Overall Assessment
This company scores 9/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 0 register as strengths (avg 0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (40.15), Price/Book (5.09) suggest expensive pricing. Growth concerns include Revenue Growth at -59.00%, which may limit upside. Profitability pressure is visible in Operating Margin at -2509.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -2509.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -59.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HIND Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HIND's Price-to-Sales ratio of 40.15x trades 122% above its historical average of 18.09x (83th percentile), historically expensive. The current valuation is 85% below its historical high of 259.64x set in Oct 2016, and 66817% above its historical low of 0.06x in Nov 2022. Over the past 12 months, the PS ratio has expanded from ~0.3x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Vyome Holdings, Inc. (HIND) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Vyome Holdings, Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 344,590 with 59% decline year-over-year.
Key Findings
Spending 77% of revenue (264,642) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 59% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -1M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Vyome Holdings, Inc..
Bottom Line
Vyome Holdings, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Vyome Holdings, Inc.(HIND)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company is headquartered in Princeton, New Jersey.